Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12857/117703
Title: Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation
Authors: Zambello, Renato 
Bonaldi, Laura
Berno, Tamara 
Martines, Annalisa 
Sechettin, Erica 
De March, Elena 
Branca, Antonio 
Lico, Albana 
Minotto, Claudia 
Briani, Chiara 
Gurrieri, Carmela 
Temporin, Francesca 
Battistutta, Claudia
Piazza, Francesco 
Cavraro, Monica 
Trentin, Livio 
Semenzato, Gianpietro 
Keywords: Continous treatment;Cytogenetic;Lenalidomide;Real life evaluation;Refractory-relapsed multiple myeloma
Keywords Plus: IN-SITU HYBRIDIZATION;PLUS DEXAMETHASONE;PROGNOSTIC VALUE;SURVIVAL;OUTCOMES;THERAPY;GAIN;1Q21
Mesh headings: Antineoplastic Combined Chemotherapy Protocols;Multiple Myeloma
Secondary Mesh headings: Adult;Aged;Aged, 80 and over;Chromosome Banding;Dexamethasone;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Lenalidomide;Male;Middle Aged;Proportional Hazards Models;Recurrence;Retrospective Studies;Thalidomide;Treatment Outcome;Young Adult
Issue Date: Oct-2015
Publisher: CIG MEDIA GROUP, LP
Journal: Clinical lymphoma, myeloma & leukemia 
Abstract: 
In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression.
URI: http://hdl.handle.net/20.500.12857/117703
ISSN: 21522650
DOI: 10.1016/j.clml.2015.05.003
Appears in Collections:Articles

Show full item record

SCOPUSTM   
Citations

2
checked on Aug 31, 2020

WEB OF SCIENCETM
Citations

2
checked on Dec 2, 2021

Page view(s) 5

2
checked on Dec 6, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.